GYRE logo

Gyre Therapeutics (GYRE)

Profile

Full Name

Gyre Therapeutics, Inc.

Ticker Symbol

GYRE

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

April 12, 2006

Indexes

Not included

Website

http://www.gyretx.com

Employees

579

Key Details

Price

$9.07(-0.55%)

Market cap

$849.06M(Small cap)

Last Dividend

$7.20

TTM Dividend yield

-

Annual revenue

$105.76M(-6.78% YoY)

Annual EPS

$0.05(+103.55% YoY)

PE ratio

181.40

Next earnings date

May 9, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$9.07
GYRE price is $9.07

30-Day Relative Volume

0.20
GYRE 30-day relative volume is 0.20

Price Performance

Price Most recent change

-0.55%
GYRE price was down -0.55% on Apr 25, 2025

Price YTD change

-25.04%
GYRE price is down -25.04% since January 1st

Price 1-year change

-44.46%
GYRE price is down -44.46% year-on-year

Price 3-year change

+7.98%
GYRE price is up +7.98% over the past 3 years

Price Range

Price All-time high

$47990.25
GYRE price is currently -99.98% below its historical high of $47990.25

Price 3-year low

$2.85
GYRE price is currently +218.25% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$849.06M
GYRE market capitalization is $849.06 million

Market cap 3-year change

-
GYRE market capitalization 3-year change is unknown

Market cap All-time high

$2.27B
GYRE market capitalization is currently -62.65% below its historical high of $2.27 billion

Market cap sector rank

74.15%
GYRE market capitalization is higher than 74.15% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+9.53%
GYRE shares outstanding is up +9.53% year-on-year

Shares Outstanding 3-Year Change

-
GYRE shares outstanding 3-year change is unknown

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.18
GYRE beta is 1.18

200-day SMA

$11.86
GYRE price is currently -23.52% below its 200-day simple moving average

50-day SMA

$9.75
GYRE price is currently -6.97% below its 50-day simple moving average

RSI

52.76
GYRE 14-day relative strength index is 52.76

Volume

0.20
GYRE 30-day relative volume is 0.20

ATR

$0.87
GYRE average true range is $0.87

10-day Historical Volatility

89.89%
GYRE 10-day historical volatility is 89.89%

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Last Paid Dividend

$7.20
GYRE last dividend was $7.20 per share, with an ex-dividend date of January 13, 2023

Next Dividend

-
GYRE next dividend has not yet been announced

Dividend per share

Dividend per share

-
GYRE annual dividend per share value is unknown

Dividend per share Sector Rank

-
GYRE annual dividend per share is unknown

Dividend per share 1-Year Change

-
GYRE annual dividend per share 1-year change is unknown

Dividend per share 3-Year Change

-
GYRE annual dividend per share 3-year change is unknown

Dividend yield

Dividend yield

-
GYRE annual dividend yield value is unknown

Dividend yield Sector Rank

-
GYRE annual dividend yield is unknown

Other

Payout ratio

-
GYRE annual payout ratio value is unknown

Dividends paid

-
GYRE annual dividends paid value is unknown

Free cash flow

-$6.77M
GYRE annual free cash flow is -$6.77 million

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$105.76M
GYRE annual revenue is $105.76 million

Revenue Analysts estimate

$126.50M
GYRE annual revenue is currently -16.40% lower than the consensus analysts' forecast

Revenue 1-year change

-6.78%
GYRE annual revenue is down -6.78% year-on-year

Revenue Sector rank

56.54%
GYRE annual revenue is higher than 56.54% of companies in Healthcare sector

EPS

EPS

$0.05
GYRE annual earnings per share is $0.05

EPS Analysts estimate

-
GYRE annual earnings per share consensus analysts' forecast is unknown

EPS 1-year change

+103.55%
GYRE annual earnings per share is up +103.55% year-on-year

EPS Sector rank

82.89%
GYRE annual earnings per share is higher than 82.89% of companies in Healthcare sector

Profit

Gross profit

$101.87M
GYRE annual gross profit is $101.87 million

Gross margin

96.33%
GYRE annual gross profit margin is 96.33%

Operating profit

$16.23M
GYRE annual operating income is $16.23 million

Operating margin

15.35%
GYRE annual operating profit margin is 15.35%

Net income

$12.09M
GYRE annual net profit is $12.09 million

Net margin

11.43%
GYRE annual net profit margin is 11.43%

Expenses

Total expenses

$89.53M
GYRE annual total expenses is $89.53 million

Operating expenses

$85.64M
GYRE annual total operating expenses is $85.64 million

Cost of goods sold

$3.88M
GYRE annual cost of goods sold is $3.88 million

Selling, general & administrative expenses

$73.62M
GYRE annual SGA is $73.62 million

Depreciation and amortization

$1.59M
GYRE annual depreciation & amortization is $1.59 million

Interest expense

-
GYRE annual interest expense value is unknown

Income tax

$5.32M
GYRE annual income tax is $5.32 million

EBIT & EBITDA

EBIT

$16.23M
GYRE annual earnings before interest & taxes is $16.23 million

EBITDA

$17.82M
GYRE annual EBITDA is $17.82 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$125.41M
GYRE annual total assets is $125.41 million

Non current assets

$60.62M
GYRE annual long term assets is $60.62 million

Current assets

$64.79M
GYRE annual total current assets is $64.79 million

Cash and cash equivalents

$11.81M
GYRE annual cash & cash equivalents is $11.81 million

Accounts receivable

$19.59M
GYRE annual accounts receivable is $19.59 million

Inventory

$6.34M
GYRE annual inventory is $6.34 million

Liabilities

Total liabilities

$27.00M
GYRE annual total liabilities is $27.00 million

Long term liabilities

$7.49M
GYRE annual total long term liabilities is $7.49 million

Current liabilities

$19.52M
GYRE annual total current liabilities is $19.52 million

Accounts payable

$108.00K
GYRE annual accounts payable is $108.00 thousand

Debt

Total debt

$1.60M
GYRE annual total debt is $1.60 million

Total debt 1-year change

+290.71%
GYRE annual total debt is up +290.71% year-on-year

Long term debt

$885.00K
GYRE annual long term debt is $885.00 thousand

Short term debt

$713.00K
GYRE annual short term debt is $713.00 thousand

Equity & Capital

Shareholders equity

$63.32M
GYRE annual stockholders equity is $63.32 million

Book value

$63.32M
GYRE annual book value is $63.32 million

Retained earnings

-$73.45M
GYRE annual retained earnings is -$73.45 million

Working capital

$45.27M
GYRE annual working capital is $45.27 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$3.64M
GYRE annual cash flow from operations is -$3.64 million

Cash from operations 1-year change

-114.06%
GYRE annual cash flow from operations is down -114.06% year-on-year

Cash from investing

-$19.88M
GYRE annual cash flow from investing activities is -$19.88 million

Cash from investing 1-year change

-0.63%
GYRE annual cash flow from investing activities is down -0.63% year-on-year

Cash from financing

$2.10M
GYRE annual cash flow from financing activities is $2.10 million

Cash from financing 1-year change

-15.92%
GYRE annual cash flow from financing activities is down -15.92% year-on-year

CAPEX

CAPEX

$3.13M
GYRE annual capital expenditures is $3.13 million

CAPEX 1-year change

-63.57%
GYRE annual capital expenditures is down -63.57% year-on-year

Free Cash Flow

Free cash flow

-$6.77M
GYRE annual free cash flow is -$6.77 million

Free cash flow 1-year change

-139.11%
GYRE annual free cash flow is down -139.11% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

96.33%
GYRE annual gross profit margin is 96.33%

Operating margin

15.35%
GYRE annual operating profit margin is 15.35%

Net margin

11.43%
GYRE annual net profit margin is 11.43%

ROA & ROE

ROA

9.99%
GYRE annual return on assets is 9.99%

ROE

21.51%
GYRE annual return on equity is 21.51%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

181.40
GYRE price to earnings ratio is 181.40

PE ratio Sector rank

93.63%
GYRE price to earnings ratio is higher than 93.63% of companies in Healthcare sector

PB Ratio

PB ratio

13.41
GYRE price to book ratio is 13.41

PB ratio Sector rank

94.27%
GYRE price to book ratio is higher than 94.27% of companies in Healthcare sector

PS Ratio

PS ratio

8.03
GYRE price to sales ratio is 8.03

PS ratio Sector rank

74.16%
GYRE price to sales ratio is higher than 74.16% of companies in Healthcare sector

Enterprise value

Enterprise value

$838.85M
GYRE enterprise value is $838.85 million

Enterprise value Sector rank

73.81%
GYRE enterprise value is higher than 73.81% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

47.08
GYRE EV/EBITDA is 47.08

EV/EBITDA Sector rank

96.83%
GYRE EV/EBITDA is higher than 96.83% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

3.32
GYRE annual current ratio is 3.32

Quick ratio

2.99
GYRE annual quick ratio is 2.99

Leverage

Debt to equity

0.00
GYRE annual debt to equity ratio is 0.00

Interest coverage ratio

-
GYRE annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

4
GYRE piotroski f-score is 4

Altman Z-Score

19.75
GYRE altman z-score is 19.75

Analyst ratings

Recent major analysts updates

No data about analysts updates

Institutional Ownership

Similar stocks

AVDL logo
Avadel Pharmaceuticals (AVDL)
SYRE logo
Spyre Therapeutics (SYRE)
COLL logo
Collegium Pharmaceutical (COLL)
VIR logo
Vir Biotechnology (VIR)
NTLA logo
Intellia Therapeutics (NTLA)
MLYS logo
Mineralys Therapeutics (MLYS)
ESTA logo
Establishment Labs Holdings (ESTA)
ZYME logo
Zymeworks (ZYME)
RCUS logo
Arcus Biosciences (RCUS)
  • What is the ticker symbol for Gyre Therapeutics?
  • Does Gyre Therapeutics pay dividends?
  • What sector is Gyre Therapeutics in?
  • What industry is Gyre Therapeutics in?
  • What country is Gyre Therapeutics based in?
  • When did Gyre Therapeutics go public?
  • Is Gyre Therapeutics in the S&P 500?
  • Is Gyre Therapeutics in the NASDAQ 100?
  • Is Gyre Therapeutics in the Dow Jones?
  • When was Gyre Therapeutics's last earnings report?
  • When does Gyre Therapeutics report earnings?
  • Should I buy Gyre Therapeutics stock now?

What is the ticker symbol for Gyre Therapeutics?

The ticker symbol for Gyre Therapeutics is NASDAQ:GYRE

Does Gyre Therapeutics pay dividends?

No, Gyre Therapeutics does not pay dividends

What sector is Gyre Therapeutics in?

Gyre Therapeutics is in the Healthcare sector

What industry is Gyre Therapeutics in?

Gyre Therapeutics is in the Biotechnology industry

What country is Gyre Therapeutics based in?

Gyre Therapeutics is headquartered in United States

When did Gyre Therapeutics go public?

Gyre Therapeutics's initial public offering (IPO) was on April 12, 2006

Is Gyre Therapeutics in the S&P 500?

No, Gyre Therapeutics is not included in the S&P 500 index

Is Gyre Therapeutics in the NASDAQ 100?

No, Gyre Therapeutics is not included in the NASDAQ 100 index

Is Gyre Therapeutics in the Dow Jones?

No, Gyre Therapeutics is not included in the Dow Jones index

When was Gyre Therapeutics's last earnings report?

Gyre Therapeutics's most recent earnings report was on Mar 17, 2025

When does Gyre Therapeutics report earnings?

The next expected earnings date for Gyre Therapeutics is May 9, 2025

Should I buy Gyre Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page